A Phase 4 interventional study of Micronized progesterone 200 MG and Micronized Progesterone 100 MG in Turner Syndrome and Primary Ovarian Insufficiency (Poi), sponsored by Children's Mercy Hospital Kansas City. Recruiting at 1 site in United States. Open to female participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Children's Mercy Hospital Kansas City · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Turner Syndrome with a site in United States — 9 open to participants now, 13 under way, 3 of them phase 3. Turner Syndrome · United States.
Among the 50 studies in Turner Syndrome with a site in United States, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 8 of the 12 other live ones, and was the 48th registered.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
Browse Turner Syndrome studies →9 of the 50 studies in Turner Syndrome with a site in United States are open now. Recruiting first, the newest first:
Ascendis Pharma A/S · Sites in United States, France, Germany and 4 more countries
Ages 2–17
Roopa Kanakatti Shankar, MBBS, MS · Sites in United States
Ages 3–11 · Women only
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 2–35
University of Colorado, Denver · Sites in United States
Women only
The University of Texas Health Science Center, Houston · Sites in United States
Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.
This study: 12 Years to 20 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Median enrollment 75 across the 22 interventional studies, 256 across the 28 observational. Of the 33 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 50 have an industry lead sponsor. The 10 most frequent:
Children's Mercy Hospital Kansas City is the lead sponsor of 210 studies on the registry; 20 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
Children's Mercy Hospital Kansas City has 1 study filed under Turner Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Turner Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07784582Children's National Research InstitutePre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies in Turner Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prescribed adult dosing* of transdermal or oral estradiol for estrogen replacement therapy.
*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle.
Drug: Micronized progesterone 200 MG
Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
Drug: Micronized Progesterone 100 MG
Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle
Also known as: Sequential
Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
Also known as: Continuous
Menstrual bleeding patterns as assessed by the Pictorial Bleeding Assessment Chart (PBAC)
PBAC is one of the most common scoring systems used in the literature to quantify menstrual blood loss (MBL) using a pictorial scoring system, with a higher score representing a larger MBL and a score \>100 qualifying as heavy menstrual bleeding
Time frame: From enrollment to end of treatment at day 90.
Menstrual distress questionnaire (MEDI-Q)
The Menstrual distress questionnaire (MEDI-Q) is a valid and reliable instrument for the assessment of menstrual distress and its impact on psychological well-being. This tool can be utilized in research and clinical settings to comprehensively investigate the impact of menstruation on various populations
Time frame: From enrollment to end of treatment at day 90.
Endometrial thickness.
Endometrial thickness measured by transabdominal pelvic ultrasound.
Time frame: On study day 90 +/- 14 days.
Plan to share: No — Protect confidentiality of individuals with this rare disease (Turner syndrome).
Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Progesterone
Children's Mercy Hospital Kansas City →